Full Press Release Details
Patients with pancreaticobiliary cancers often develop jaundice as a result of tissue ingrowth that blocks ducts that enable bile to drain out of the GI tract. The Habib EndoHPB probe coagulates this tissue to help ensure that the fluids are able to drain, which can result in an improvement in a patient's quality of life. In addition to coagulating tissue, physicians will frequently place stents to ensure that the GI tract remains open during palliative care.
"As we continue to search for ways to treat pancreaticobiliary cancers, we also seek to improve the quality of life for patients living with a cancer diagnosis today," said Art Butcher , senior vice president and president, Endoscopy, Boston Scientific. "We are committed to exploring innovative options to help increase the chance of early diagnosis, improve treatment and advance the ability to remove cancers located in challenging areas of the gastrointestinal tract."
The Habib EndoHPB probe is cleared by the U.S. Food and Drug Administration and received CE mark in the European Union.
The Boston Scientific Endoscopy business offers a range of devices and solutions that help with the diagnosis, treatment and management of GI and pulmonary diseases. In November 2016 , Boston Scientific acquired EndoChoice Holdings, Inc., adding pathology services, infection prevention and a range of single-use devices to its portfolio. In addition, the company is developing a range of devices to expand the field of minimally invasive endoluminal procedures as alternatives to conventional surgery for the removal of precancerous lesions and malignant tumors in the GI tract.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
1 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf 2Cholangiocarcinoma: Early Diagnosis Is Key." Medscape, 28 Mar. 2013 , www.medscape.com/viewarticle/781524 . 3Cidon, E. Una. "Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies." Clinical Medicine Insights. Oncology . Libertas Academica, 12 May 2016 . Web. 08 May 2017 . 4"Pancreatic Cancer Surgical Treatment and Whipple Procedure." Pancreatica. Cancer Patients Alliance, n.d. Web. 08 May 2017 .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, regulatory approvals, product development and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACTS: Catherine Brady Boston Scientific Corporation 508-683-4797 (office) [email protected]
Susie Lisa , CFA Investor Relations Boston Scientific Corporation (508) 683-5565 (office) [email protected]
SOURCE Boston Scientific Corporation